RT Journal Article
SR Electronic
T1 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A767
OP A767
DO 10.1136/jitc-2023-SITC2023.0676
VO 11
IS Suppl 1
A1 Fisher, Terrence
A1 Evans, Elizabeth
A1 Mallow, Crystal
A1 Foster, Amber
A1 Leonard, John
A1 Chaney, Marya
A1 Mekhail, Tarek
A1 Seetharamu, Nagashree
A1 Steuer, Conor
A1 Saba, Nabil F
A1 Adkins, Douglas
A1 Thaddeus Beck, J
A1 Algazi, Alain
A1 Burtness, Barbara
A1 Baumgart, Megan
A1 Hager, Steven
A1 Chay, Christopher
A1 Spira, Alexander
A1 Zauderer, Maurice
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A767.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.